Weekly high-dose cisplatin is a feasible treatment option: Analysis on prognostic factors for toxicity in 400 patients

British Journal of Cancer

Volumn 88, Issue 8, 2003, Pages 1199-1206

  De Jongh, F E ^a,b   Van Veen, R N ^a   Veltman, S J ^a   De Wit, R ^a   Van Der Burg, M E L ^a   Van Den Bent, M J ^a   Planting, A S Th ^a   Graveland, W J ^a   Stoter, G ^a   Verweij, J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b IKAZIA HOSPITAL   (Netherlands)

Author keywords

Chemotherapy; Cisplatin; Prognostic factors; Toxicity

Indexed keywords

ALBUMIN; CISPLATIN; ETOPOSIDE; PACLITAXEL; SODIUM CHLORIDE;

ADULT; ANEMIA; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE PREDISPOSITION; DOSE CALCULATION; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; GASTROINTESTINAL TOXICITY; HEARING LOSS; HUMAN; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; LEUKOPENIA; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; OTOTOXICITY; PATIENT COMPLIANCE; POLYNEUROPATHY; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SENESCENCE; SEX DIFFERENCE; SIDE EFFECT; SMOKING; SOLID TUMOR; THROMBOCYTOPENIA; TREATMENT PLANNING; VOMITING;

ADULT; AGED; CISPLATIN; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; ODDS RATIO; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 0038147117     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6600884     Document Type: Article

References (37)

1. Bajorin DF, Bosl GJ, Alcock NW, Niedzwiecki D, Gallina E, Shurgot B (1986) Pharmacokinetics of cis-diamminedichloroplatinum(II) after administration in hypertonic saline. Cancer Res 46: 5969-5972
2. Blakley BW, Gupta AK, Myers SF, Schwan S (1994) Risk factors for ototoxicity due to cisplatin. Arch Otolaryngol Head Neck Surg 120: 541-546
3. Cavaletti G, Marzorati L, Bogliun G, Colombo N, Marzola M, Pitelli MR, Tredici G (1992) Cisplatin-induced peripheral neurotoxicity is dependent on total-dose intensity and single-dose intensity. Cancer 69: 203-207
4. Cersosimo RJ (1989) Cisplatin neurotoxicity. Cancer Treat Rev 16: 195-211
5. Connelly E, Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J (1996) Paclitaxel delivered at a 3-hr infusion with cisplatin in patients with gynecologic cancers: unexpected incidence of neurotoxicity. Gynecol Oncol 62: 166-168
6. de Jongh FE, Verweij J, Loos WJ, de Wit R, de Jonge MJA, Planting AST, Nooter K, Stoter G, Sparreboom A (2001) Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure. J Clin Oncol 19: 3733-3739
7. de Vos AI, Nooter K, Verweij J, Loos WJ, Brouwer E, de Bruijn P, Ruijgrok EJ, van der Burg MEL, Stoter G, Sparreboom A (1997) Differential modulation of cisplatin accumulation in leukocytes and tumor cell lines by the paclitaxel vehicle Cremophor EL. Ann Oncol 8: 1145-1150
8. Earhart RH, Martin PA, Tutsch KD, Ertürk E, Wheeler RH, Bull FE (1983) Improvement in the therapeutic index of cisplatin (NSC 119875) by pharmacologically induced chloruresis in the rat. Cancer Res 43: 1187-1194
9. Gelderblom H, Loos WJ, Verweij J, van der Burg MEL, de Jonge MJA, Brouwer E, Nooter K, Stoter G, Sparreboom A (2002) Modulation of cisplatin pharmacodynamics by Cremophor EL: experimental and clinical studies. Eur J Cancer 38: 205-213
10. Hilkens PHE, Planting AST, van der Burg MEL, Moll JWB, van Putten WLJ, Vecht CJ, van den Bent MJ (1994) Clinical course and risk factors of neurotoxicity following cisplatin in an intensive dosing schedule. Eur J Neurol 1: 45-50
11. Hilkens PHE, Pronk LC, Verweij J, Vecht CJ, van Putten WLJ, van den Bent MJ (1997) Peripheral neuropathy induced by combination chemotherapy of docetaxel and cisplatin. Br J Cancer 75: 417-422
12. Hilkens PHE, van der Burg MEL, Moll JWB, Planting AST, van Putten WLJ, Vecht CJ, van den Bent MJ (1995) Neurotoxicity is not enhanced by increased dose intensities of cisplatin administration. Eur J Cancer 31A: 678-681
13. 2 +, and the hydrolysis product of cisplatin in the rat. Cancer Chemother Pharmacol 29: 29-32
14. Lagrange JL, Médecin B, Etienne MC, Pivot X, Cassuto-Viguier E, Reneé N, Thyss A, Ferrero JM, Otto J, François E, Milano G (1997) Cisplatin nephrotoxicity: a multivariate analysis of potential predisposing factors. Pharmacother 17: 1246-1253
15. Laurell G, Jungnelius U (1990) High-dose cisplatin treatment: hearing loss and plasma concentrations. Laryngoscope 100: 724-734
16. Litterst CL (1981) Alterations in the toxicity of cis-dichlorodiammineplatinum-II and in tissue localization of platinum as a function of NaCl concentration in the vehicle of administration. Toxicol Appl Pharmacol 61: 99-108
17. Maytin M, Leopold J, Loscalzo J (1999) Oxidant stress in the vasculature. Curr Atheroscler Rep 1: 156-164
18. Merouani A, Davidson SA, Schrier RW (1997) Increased nephrotoxicity of combination taxol and cisplatin chemotherapy in gynecologic cancers as compared to cisplatin alone. Am J Nephrol 17: 53-58
19. Nagai N, Kinoshita M, Ogata H, Tsujino D, Wada Y, Someya K, Ohno T, Masuhara K, Tanaka Y, Kato K, Nagai H, Yokoyama A, Kurita Y (1996) Relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity after intravenous infusions of cisplatin to cancer patients. Cancer Chemother Pharmacol 39: 131-137
20. Nagai N, Ogata H (1997) Quantitative relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity in rats: importance of area under the concentration - time curve (AUC) as the major toxicodynamic determinant in vivo. Cancer Chemother Pharmacol 40: 11-18
21. Ozols RF, Corden BJ, Jacob J, Wesley MN, Ostchega Y, Young RC (1984) High-dose cisplatin in hypertonic saline. Ann Intern Med 100: 19-24
22. Pinzani V, Bressolle F, Haug IJ, Galtier M, Blayac JP, Balmès P (1994) Cisplatin-induced renal toxicity and toxicity-modulating strategies: a review. Cancer Chemother Pharmacol 35: 1-9
23. Planting AST, Kho GS, van der Burg MEL, Goey SH, Schellens JHM, van den Bent MJ, van der Gaast A, de Boer-Dennert M, Stoter G, Verweij J (1997a) A phase II study of weekly high-dose cisplatin combined with oral etoposide in advanced non-small cell lung cancer. Cancer Chemother Pharmacol 40: 347-352
24. Planting AST, de Mulder PHM, de Graeff A, Verweij J (1997b) Phase II study of weekly high-dose cisplatin for six cycles in patients with locally advanced squamous cell carcinoma of the head and neck. Eur J Cancer 33: 61-65
25. Planting AST, Schellens JHM, Goey SH, van der Burg MEL, de Boer-Dennert M, Stoter G, Verweij J (1994) Weekly high-dose cisplatin in malignant pleural mesothelioma. Ann Oncol 5: 373-374
26. Planting AST, van der Burg MEL, de Boer-Dennert M, Stoter G, Verweij J (1993) Phase I/II study of a short course of weekly cisplatin in patients with advanced solid tumours. Br J Cancer 68: 789-792
27. Planting AST, van der Burg MEL, de Boer-Dennert M, Stoter G, Verweij J (1995a) Phase I study of weekly high-dose cisplatin combined with long term oral etoposide in advanced solid tumors. Ann Oncol 6: 190-192
28. Planting AST, van der Burg MEL, Goey SH, Schellens JHM, van den Bent MJ, de Boer-Dennert M, Stoter G, Verweij J (1995b) Phase II study of a short course of weekly high-dose cisplatin combined with long term oral etoposide in pleural mesothelioma. Ann Oncol 6: 613-615
29. Reddel RR, Kefford RF, Grant JM, Coates AS, Fox RM, Tattersall HN (1982) Ototoxicity in patients receiving cisplatin: importance of dose and method of drug administration. Cancer Treat Rep 66: 19-23
30. Reece PA, Stafford I, Russell J, Khan M, Gill PG (1987) Creatinine clearance as a predictor of ultrafilterable platinum disposition in cancer patients treated with cisplatin: relationship between peak ultrafilterable platinum plasma levels and nephrotoxicity. J Clin Oncol 5: 304-309
31. Rowinsky EK, Gilbert MR, McGuire WP, Noe DA, Grochow LB, Forastiere AA, Ettinger DS, Lubejko BG, Clark B, Sartorius SE, Cornblath DR, Hendricks CB, Donehower RC (1991) Sequences of taxol and cisplatin: a phase I and pharmacologic study. J Clin Oncol 9: 1692-1703
32. Schaeffer SD, Post JD, Close LG, Wright CG (1985) Ototoxicity of low- and moderate-dose cisplatin. Cancer 56: 1934-1939
33. Stewart DJ, Dulberg CS, Mikhael NZ, Redmond D, Montpetit VAJ, Goel R (1997) Association of cisplatin nephrotoxicity with patient characteristics and cisplatin administration methods. Cancer Chemother Pharmacol 40: 293-308
34. van den Bent MJ, Pronk L, Sillevis Smitt PA, Vecht CJ, Eskens FA, Verweij J (1999) Phase II study of weekly dose-intensified cisplatin chemotherapy with oral etoposide in recurrent glioma. J Neuro-oncol 44: 59-64
35. van den Bent MJ, van Putten WLJ, Hilkens PHE, de Wit R, van der Burg MEL (2002) Retreatment with dose-dense weekly cisplatin after previous cisplatin chemotherapy is not complicated by significant neuro-toxicity. Eur J Cancer 38: 387-391
36. van der Burg MEL, de Wit R, Stoter G, Verweij J (1998) Phase I study of weekly cisplatin and weekly or 4-weekly taxol: a highly active regimen in advanced epithelial ovarian cancer. Proc Am Soc Clin Oncol 17: abstract 1370
37. van der Burg MEL, de Wit R, van Putten WLJ, Logmans A, Kruit WHJ, Stoter G, Verweij J (2002) weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancer. Br J Cancer 86: 19-25